Curcumin Analogue B-155 Outperforms Natural Curcumin in Ovarian Cancer Preclinical Study (2026)
A 2026 preclinical study found that the synthetic curcumin analogue B-155 demonstrates significantly greater cytotoxicity than natural curcumin in SKOV3 ovarian cancer cells, with effects including G2/M cell-cycle arrest, apoptosis, and p38 MAPK binding. The study is limited to in vitro data.
By Sanare Lab · August 8, 2026 · 5 min read
Key Takeaway
A 2026 preclinical study in SKOV3 ovarian cancer cells found that the synthetic curcumin analogue B-155 demonstrated significantly greater cytotoxicity than natural curcumin and analogue B-143, associated with G2/M cell-cycle arrest, increased apoptosis, and suppression of cell migration. Computational analysis showed favorable binding of B-155 to the p38α MAPK ATP-binding pocket. Both B-155 and natural curcumin suppressed migration, but curcumin more consistently downregulated epithelial-mesenchymal transition (EMT) and stress-response genes. These findings are preclinical only and do not establish clinical efficacy.
Ovarian cancer remains one of the deadliest gynecological malignancies, largely because it is often diagnosed at advanced stages, frequently recurs, and rapidly develops resistance to chemotherapy. New therapeutic approaches are urgently needed to improve outcomes for patients with recurrent or resistant disease.
Curcumin, a natural compound derived from turmeric (Curcuma longa), has been extensively studied for its anticancer properties. However, its poor bioavailability and rapid metabolism in the human body limit its clinical utility. Researchers have synthesized structural analogues to enhance curcumin's biological activity while maintaining its favorable safety profile.
Table of Contents
- Study Design and Methods
- Key Findings: B-155 Shows Superior Activity
- Molecular Insights: p38 MAPK Binding
- Clinical Implications and Limitations
- Frequently Asked Questions
Study Design and Methods
The study used SKOV3 ovarian cancer cells as the experimental model. Three compounds were evaluated: natural curcumin, and two synthetic curcumin analogues designated B-143 and B-155. Cytotoxicity was assessed using standard cell viability assays. Cell-cycle distribution was analyzed by flow cytometry. Apoptosis (programmed cell death) was measured, and cell migration was evaluated using wound-healing assays. Network pharmacology analysis was employed to predict molecular targets and signaling pathways. Quantitative polymerase chain reaction (RT-qPCR) was used to measure expression of genes related to angiogenesis (blood vessel formation), metastasis (cancer spread), and epithelial-mesenchymal transition (EMT, a process by which cancer cells become more invasive). Molecular docking and molecular dynamics simulations were performed to evaluate the binding of B-155 to the p38α MAPK (mitogen-activated protein kinase 14) protein, a known regulator of cell proliferation and survival.
Key Findings: B-155 Shows Superior Activity
The study revealed that B-155 exhibited significantly greater cytotoxicity compared to both natural curcumin and analogue B-143. This enhanced activity was associated with G2/M cell-cycle arrest (blocking cells at the G2/M checkpoint, preventing them from dividing) and increased apoptosis. Both B-155 and natural curcumin effectively suppressed SKOV3 cell migration, whereas B-143 showed minimal effects. Network pharmacology analyses predicted that B-143 and B-155 interact with overlapping yet distinct angiogenesis- and metastasis-associated signaling networks, suggesting potential associations with multiple pathways relevant to ovarian cancer. RT-qPCR analysis revealed that natural curcumin consistently downregulated genes linked to EMT and cellular stress, while B-143 and B-155 displayed only partial adaptive responses in several angiogenesis and metastasis transcription markers.
Molecular Insights: p38 MAPK Binding
To explore the molecular basis of B-155's enhanced activity, computational modeling was performed using p38α MAPK (MAPK14) as a candidate target. Molecular docking analysis demonstrated favorable binding of B-155 within the ATP-binding pocket of p38 MAPK. Molecular dynamics simulations over 100 nanoseconds confirmed stable protein-ligand complex formation, suggesting a plausible mechanism for B-155's anticancer effects. However, these computational predictions were not validated with experimental biochemical assays such as kinase inhibition assays or surface plasmon resonance in this study.
Clinical Implications and Limitations
The study highlights the influence of structural modifications on curcumin's biological activity and supports B-155 as a promising curcumin analogue for further preclinical investigation. However, several important limitations must be acknowledged. The study was conducted exclusively in SKOV3 cells, a single ovarian cancer cell line. No in vivo (animal) models were used to evaluate pharmacokinetics, distribution, metabolism, or toxicity. The computational predictions of p38 MAPK binding were not experimentally validated. Additionally, the study did not compare B-155 against standard chemotherapy agents such as carboplatin or paclitaxel. Clinical translation will require extensive pharmacokinetic and toxicology studies, followed by phase I clinical trials to establish safety and efficacy in humans.
For background, see our guide to what the curcumin and cancer research shows.
You can map out a weight-based schedule using our dosage calculator.
Frequently Asked Questions
What are curcumin analogues?
Curcumin analogues are chemically modified versions of curcumin, a natural compound found in turmeric. Scientists create these analogues to improve properties such as potency, stability, bioavailability (how much of a drug reaches the bloodstream), and metabolic resistance.
What is the G2/M cell-cycle arrest?
The G2/M checkpoint is a stage in the cell division cycle where the cell verifies that DNA is undamaged and ready for mitosis (cell division). If a drug causes G2/M arrest, it blocks cancer cells from dividing and multiplying, which can lead to programmed cell death (apoptosis).
What is p38 MAPK?
p38 MAPK (mitogen-activated protein kinase) is a family of enzymes involved in regulating cell proliferation, differentiation, and survival. In cancer, p38 MAPK can be either tumor-promoting or tumor-suppressing depending on the context. In this study, B-155 was predicted to bind the ATP-binding pocket of p38α MAPK, potentially inhibiting its kinase activity.
What is epithelial-mesenchymal transition (EMT)?
EMT is a biological process in which epithelial cells (cells that form barriers) lose their characteristics and gain properties of mesenchymal cells (cells that can move and invade). In cancer, EMT is associated with increased metastasis, drug resistance, and poor prognosis.
Does this study mean B-155 can treat ovarian cancer?
No. This study provides preclinical evidence from a single cell line only. No animal models, pharmacokinetic data, or human trials were conducted. It is far too early to draw conclusions about clinical efficacy or safety.
This study compared natural turmeric extract (curcumin) against two lab-created versions called B-143 and B-155 in ovarian cancer cells. B-155 was the most potent at killing cancer cells, blocking them from dividing, and stopping them from moving. It was also predicted to bind to a protein called p38 MAPK, which controls cell growth signals. Natural curcumin was better at turning off genes that help cancer spread. However, this was only tested in a petri dish with one type of cancer cell. No animal tests or human trials were done, so it is far too early to know if B-155 would work in patients.
Shop Sanare Lab
Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.
Lab-tested curcumin supplement — 120 capsules, 360 mg per serving.
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
- Murwanti R, Anargya RDP, Saputra BW. Pharmacological evaluation reveals distinct anti-proliferative and migration-associated effects of curcumin analogues B-143 and B-155 in ovarian cancer cells. Mol Biol Rep. 2026;51(1):12455. doi:10.1007/s11033-026-12455-w
Medical Disclaimer
This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. The content discusses preclinical research findings and should not be interpreted as a recommendation for any specific therapy. Always consult a licensed healthcare professional before making any medical decisions.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.